# US 2024/0293395 A1 · NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0293395 A1
- Document ID: US20240293395A1
- Status: Published application
- Kind: A1
- Application number: 18/573,359
- Filed: 2022-06-23
- Published: 2024-09-05
- Earliest claimed: 2021-06-23
- Assignees: LDN Pharma Limited
- Applicants: LDN Pharma Limited
- Inventors: Wai Liu; Ian Thompson; Francis Hood
- Web page: https://patentgrep.com/patent/US20240293395A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine.

## Claims

### Claim 1

A method of treating a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, comprising administering an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C).

### Claim 2

A method of treating a cognitive or neurological disorder in a patient, wherein said patient is also being administered or intended to be administered an agonist of a 5-hydroxytryptamine receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), the method comprising administering a composition comprising naltrexone, or a metabolite thereof, or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine.

### Claim 3 (depends on 2)

The method of claim 2, wherein the composition comprising naltrexone, or a metabolite thereof, or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, is administered separately, simultaneously or sequentially with the agonist of a 5-hydroxytryptamine receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C).

### Claim 4 (depends on 1)

The method of claim 1, wherein naltrexone, or a metabolite or analogue thereof, is in a dosage amount of 0.01 mg-50 mg.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor is selected from the group consisting of psilocybin, psilocin, mescaline, lysergic acid diethylamide (LSD), ketamine, salvinorin A, ibotenic acid, muscimol, N,N-dimethyltryptamine (DMT), 3,4-methylenedioxymethamphetamine (MDMA), methyldiethanolamine, also known as N-methyl diethanolamine (MDEA), 3,4-methylenedioxy amphetamine (MDA), 4-Bromo-2,5-dimethoxyphenethyl-amine (2C-B); 1-(8-Bromo-2,3,6,7-tetra-hydrobenzo[1,2-b;4,5-b′]difuran-4-yl)2-amino-ethane (2C-B-fly); 4-Ethyl-2,5-dimethoxyphenethylamine (2C-E); 4-Ethyl-thio-2,5-dimethoxy phenethylamine (2C-T-2); 4-Ethylthio-2,5-dimethoxy-amphetamine (ALEPH-2); 4-Ethylthio-2,5-dimethoxyphenylbutylamine (4C-T-2); 2,5-Dimethoxy-4-ethoxyamphetamine (MEM); 2,4,5-Trimethox-amphetamine (TMA-2); 3,4,5-Trimethoxamphetamine (TMA); 2,5-Dimethoxy-4-bromo-amphetamine (DOB); 2,5-Dimethoxy-4-iodo-amphetamine (DOI); 2,5-Dimethoxy-4-methylamphetamine (DOM); 2,5-Dimethoxy-4-ethylamphet-amine (DOET); 5-Methoxy-N,N-dimethyl-tryptamine (5-MeO-DMT); N,N-Dipropyltryptamine (DPT); 5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MIPT); N,N-Diisopropyltryptamine (DIPT); 5-Methoxy-N,N-diiso-propyltryptamine (5-MeO-DIPT); 6-Fluoro-N,N-dimethyltryptamine (6-fluoro-DMT); lisuride; ibogaine; cis-2a; RR-2b; SS-2c; 2-Ethyl-5-methoxy-N,N-dimethyltryptamine (EMDT), serotonin hydrochloride, m-chlorophenylbiguanide hydrochloride, N-methylquipazine dimaleate, PSEM 895, quipazine dimaleate, RS56812 hydrochloride, serotonin hydrochloride, SR7227 hydrochloride, 1-phenylbiguanide hydrochloride, cereulide, 2-methyl-5-HT, alpha-methyltryptamine, bufotenin, chlorophenylbiguanide, ibogaine, varenicline, YM-31636, or metabolites thereof and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor is Psilocybin, ketamine, MDMA, LSD and the metabolites thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cognitive or neurological disorder is Alzheimer's disease, dementia, motor neuron disease (MND), depression, psychosis, anxiety, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), paranoia, panic attacks or flashbacks.

### Claim 10 (depends on 1)

The method of claim 1, wherein the naltrexone, or metabolite or analogue thereof, is to be administered prior to the administration of the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the naltrexone or a metabolite or analogue thereof, is to be administered between 1 to 4 days before administration of the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor.

### Claim 12 (depends on 2)

The method of claim 2, wherein the naltrexone, or a metabolite or analogue thereof, is in an oral dosage form.

### Claim 13 (depends on 2)

The method of claim 2, wherein the naltrexone, or a metabolite or analogue thereof, is in the form of a tablet or capsule.

### Claim at position 13

14-15. (canceled)

### Claim 16 (depends on 2)

A method of claim 2, wherein naltrexone, or metabolite or analogue thereof, is in a dosage amount of 0.01 mg-50 mg.

### Claim 17 (depends on 2)

The method of claim 2, wherein the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor is selected from the group consisting of psilocybin, psilocin, mescaline, lysergic acid diethylamide (LSD), ketamine, salvinorin A, ibotenic acid, muscimol, N,N-dimethyltryptamine (DMT), 3,4-methylenedioxymethamphetamine (MDMA), methyldiethanolamine, also known as N-methyl diethanolamine (MDEA), 3,4-methylenedioxy amphetamine (MDA), 4-Bromo-2,5-dimethoxyphenethyl-amine (2C-B); 1-(8-Bromo-2,3,6,7-tetra-hydrobenzo[1,2-b;4,5-b′]difuran-4-yl)2-amino-ethane (2C-B-fly); 4-Ethyl-2,5-dimethoxyphenethylamine (2C-E); 4-Ethyl-thio-2,5-dimethoxy phenethylamine (2C-T-2); 4-Ethylthio-2,5-dimethoxy-amphetamine (ALEPH-2); 4-Ethylthio-2,5-dimethoxyphenylbutylamine (4C-T-2); 2,5-Dimethoxy-4-ethoxyamphetamine (MEM); 2,4,5-Trimethox-amphetamine (TMA-2); 3,4,5-Trimethoxamphetamine (TMA); 2,5-Dimethoxy-4-bromo-amphetamine (DOB); 2,5-Dimethoxy-4-iodo-amphetamine (DOI); 2,5-Dimethoxy-4-methylamphetamine (DOM); 2,5-Dimethoxy-4-ethylamphet-amine (DOET); 5-Methoxy-N,N-dimethyl-tryptamine (5-MeO-DMT); N,N-Dipropyltryptamine (DPT); 5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MIPT); N,N-Diisopropyltryptamine (DIPT); 5-Methoxy-N, N-diiso-propyltryptamine (5-MeO-DIPT); 6-Fluoro-N,N-dimethyltryptamine (6-fluoro-DMT); lisuride; ibogaine; cis-2a; RR-2b; SS-2c; 2-Ethyl-5-methoxy-N,N-dimethyltryptamine (EMDT), serotonin hydrochloride, m-chlorophenylbiguanide hydrochloride, N-methylquipazine dimaleate, PSEM 895, quipazine dimaleate, RS56812 hydrochloride, serotonin hydrochloride, SR7227 hydrochloride, 1-phenylbiguanide hydrochloride, cereulide, 2-methyl-5-HT, alpha-methyltryptamine, bufotenin, chlorophenylbiguanide, ibogaine, varenicline, YM-31636, or metabolites thereof and combinations thereof.

### Claim 18 (depends on 2)

The method of claim 2, wherein the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor is Psilocybin, ketamine, MDMA, LSD and the metabolites thereof.

### Claim 19 (depends on 2)

The method of claim 2, wherein the cognitive or neurological disorder is Alzheimer's disease, dementia, motor neuron disease (MND), depression, psychosis, anxiety, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), paranoia, panic attacks or flashbacks.

### Claim 20 (depends on 2)

The method of claim 2, wherein the naltrexone, or metabolite or analogue thereof, is to be administered prior to the administration of the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the naltrexone or a metabolite or analogue thereof, is to be administered between 1 to 4 days before administration of the agonist of a 5-HT2A, 5-HT2B or 5-HT2C receptor.
